Introduction {#S0001}
============

Dynamic lung hyperinflation (DLH) is an important factor involved in dyspnea on exertion and exercise limitation in chronic obstructive pulmonary disease (COPD).[@CIT0001] Therefore, it is important to improve DLH by treatment. DLH involves hyperinflation of the lung, which progresses by hyperventilation with exertion. In patients with COPD, the decrease in lung elastic recoil pressure and narrowing of the peripheral bronchial lumen have been considered to induce lung hyperinflation. Therefore, exhalation may not be completed prior to the onset of the next breath, causing progressive hyperinflation.[@CIT0002] DLH refers to the variable increase in end-expiratory lung volume (EELV) above the relaxation volume of the respiratory system.[@CIT0003] As total lung capacity (TLC) remains essentially unchanged during exercise, changes in EELV during exercise can be reliably tracked by serial inspiratory capacity (IC) measurements.[@CIT0004]

There is evidence that combined administration of a long-acting muscarinic antagonist (LAMA) and long-acting β2 agonist (LABA) in patients with COPD provides increases forced expiratory volume in 1 s (FEV~1~) and reduces symptoms compared to monotherapy. Therefore, combination therapy with LAMA and LABA is recommended in patients with more severe symptoms, especially those suffering from dyspnea and exercise limitation.[@CIT0005] Previous clinical trials have demonstrated the efficacy of combined treatment with tiotropium and olodaterol on FEV~1~, health-related quality of life, and exacerbation in patients with COPD.[@CIT0006],[@CIT0007],[@CIT0008] In addition, the MORACTO trial demonstrated improvements of IC at rest and during exercise associated with tiotropium and olodaterol treatment.[@CIT0009] However, the effects of tiotropium and olodaterol on DLH following metronome-paced incremental hyperventilation (MPIH) have not been reported. Gelb et al, reported that the non-invasive simplicity of hyperventilation provides a clinically useful screening surrogate for monitoring changes in IC following exercise.[@CIT0010] Then, we reported DLH following MPIH using a spirometer. DLH is dependent on the increase in respiration rate, and we measured the decrease in IC with stepwise increases in respiration rate ([Figure 1](#F0001){ref-type="fig"}). IC is significantly reduced in patients with COPD, resulting in DLH. Therefore, we showed that DLH following MPIH is useful for assessment of pathophysiological impairment in patients with COPD.[@CIT0011] Using this method, we investigated the effects of single and combined use of LAMA and LABA in DLH.[@CIT0012],[@CIT0013] However, the effects of tiotropium and olodaterol on DLH following MPIH have not been reported. This study was performed to elucidate the effects of combined treatment with tiotropium and olodaterol on DLH following MPIH in patients with COPD.Figure 1Method for measuring dynamic lung hyperinflation by hyperventilation.**Abbreviations:** IC, inspiratory capacity; bpm, breaths/min; DLH, dynamic lung hyperinflation.

Materials and methods {#S0002}
=====================

Subjects {#S0002-S2001}
--------

The study population consisted of patients with stable COPD who visited Shinshu University Hospital (Matsumoto, Nagano, Japan) or Shinsei Hospital (Obuse, Nagano, Japan) between March 1, 2017, and December 1, 2018. Diagnosis was made according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.[@CIT0005] Patients were diagnosed based on medical history and respiratory function characterized by clinical symptoms and irreversible airflow obstruction.

All patients suffered from smoking-related COPD without α~1~ antitrypsin deficiency, and those with a smoking history of ≥10 pack-years, including current smokers, were selected for this study. In addition, as a substitute for LAMA and LABA during the washout period, patients whose symptoms responded to short-acting treatment were selected as eligible for inclusion. After receiving a thorough explanation of the study, patients who provided written consent were enrolled in the study. Patients with dysuria due to prostate hypertrophy, glaucoma, severe heart failure, symptom exacerbation and/or respiratory infection within 3 months, prior history of lung surgery, severe heart disease, or impairment or difficulty in walking due to motor or cognitive dysfunction were excluded. A history of exacerbation was defined as acute worsening of respiratory symptoms that resulted in additional therapy.[@CIT0005] Registration in this study was suspended for patients who declined to participate or withdrew their consent or if it was found after registration that the subject did not satisfy the eligibility criteria.

Ethical considerations {#S0002-S2002}
----------------------

This study was conducted in accordance with the tenets of the Declaration of Helsinki, received approval from Shinshu University Medical Ethics Committee (approval number: 3654), and has been registered in the University Hospital Medical Information Network Clinical Trials Registry system (trial ID: UMIN000027521). Individual de-identified participant data for all outcomes were used in the analysis and shared on the University Hospital Medical Information Network Clinical Trials Registry system (UMIN). The data can be accessed by registering with UMIN, and then contacting the author to receive the appropriate URL. As the number of people that can view the data is limited, this requires approval from the author. The data have already been registered on UMIN, and there is no restriction on the period of publication. Documents related to other available study are research plan on the internet.

Study design {#S0002-S2003}
------------

This study had an open-label, prospective, comparative before and after treatment design. Patients visiting the hospital for diagnosis and treatment of COPD who provided informed consent were included in the study. The combination of LAMA and LABA used consisted of Spiolto™ and Respimat®, respectively (Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan), which contained 2.5 μg of tiotropium and 2.5 μg of olodaterol per puff, respectively. We set a washout period of 3 days before the baseline examination in patients who had already been prescribed LAMA, LABA, and/or inhaled corticosteroid (ICS) based on their half-lives.[@CIT0014],[@CIT0015] In an emergency during the washout period, short-acting treatment was used to respond to symptoms. Patients first underwent baseline examination after washout consisting of COPD questionnaire followed by lung function testing. Then, we performed DLH measurement by MPIH followed by 6-min walking test (6MWT). Treatment was performed on the day after completion of the baseline examination, and consisted of administration of tiotropium/olodaterol 5/5 μg inhalation solution (2.5/2.5 μg per actuation) using a soft-mist inhaler. Patients were instructed to inhale two puffs from the inhaler, once a day, in the morning. After 8 weeks, the same test was repeated for before and after comparison following inhalation as usual. The primary outcome was defined as a decrease in IC from rest by MPIH, which is an index of DLH. The secondary outcomes were the COPD assessment test (CAT), FEV~1~, and 6-min walking distance (6MWD). As in previous studies, we also investigated whether there were correlations between changes in DLH and exercise tolerance or dyspnea on exercise associated with treatment.

Efficacy outcomes {#S0002-S2004}
-----------------

### DLH {#S0002-S2004-S3001}

In this study, DLH was measured using a spirometer (Fukuda Denshi Co., Ltd., Tokyo, Japan). The subjects regulated their breathing rate and timing in accordance with a light-emitting diode lamp for inspiration and expiration using a buzzer sound in place of a metronome. Each subject was asked to take several breaths at rest and then perform maximum inspiration followed by maximum expiration. [Figure 2](#F0002){ref-type="fig"} shows the measurement of DLH based on MPIH using a spirometer. The resting IC and vital capacity (VC) was then measured. Next, the subjects breathed in synchronization with a pulsing sound and light for 30 s at a respiratory rate of 20 breaths/min (bpm). Finally, the subjects performed maximum inspiration. After a 1--2 mins pause, the respiratory rate was increased in steps to 30 bpm for 30 s and then to 40 bpm for 30 s. At the end of each period of hyperventilation, the subjects performed maximum inspiration, and the IC was measured. The average of the valleys of three breaths just before maximum inspiration was set as the EELV, and the IC was measured from the EELV. IC measurement by each hyperventilation was repeated three times, and the machine automatically calculated the average. The ICs at rest and at hyperventilation rates of 20, 30, and 40 bpm were expressed as the IC~rest~, IC~20~, IC~30~, and IC~40~, respectively. DLH was evaluated from the decreases in IC from IC~rest~ to IC~20~ (−IC~20~; IC~20~−IC~rest~), to IC~30~ (−IC~30~; IC~30~−IC~rest~), and to IC~40~ (−IC~40~; IC~40~−IC~rest~). The ratios of −IC~20~, −IC~30~, and −IC~40~ to resting IC were expressed as ΔIC~20~, ΔIC~30~, and ΔIC~40~, respectively.Figure 2Details of dynamic lung hyperinflation measurement method using spirometer.**Abbreviations:** IC, inspiratory capacity; bpm, breaths/min; IC~rest~, IC at rest; IC~20~, IC at 20 bpm; IC~30~, IC at 30 bpm; IC~40~, IC at 40 bpm.

### Questionnaire {#S0002-S2004-S3002}

CAT was used to comprehensively evaluate the symptoms of COPD, and the Modified Medical Research Council dyspnea scale was used to evaluate subjective dyspnea.

### Lung function {#S0002-S2004-S3003}

Spirometry, FRC lung volume, and lung diffusion capacity for carbon monoxide (DL~CO~) were measured using a spirometer (Chestac 8900; Nihon Kohden Co., Ltd., Tokyo, Japan). FRC and DL~CO~ were evaluated only at the first examination. FRC was measured using a body box, after which the subject immediately inspired to TLC and expired maximally to RV, allowing calculation of lung volume and RV/TLC. For predicted values of FEV~1~ and VC, Japanese local reference data developed by the Japanese Respiratory Society were adopted,[@CIT0016] and predicted values for DL~CO~ and lung volumes (FRC, RV, and TLC) measured by body plethysmography were determined using the formulae of Nishida et al,[@CIT0017] and Boren et al,[@CIT0018], respectively. As Shinsei Hospital only has a spirometer, FRC and DL~CO~ were not measured in patients at this hospital.

### 6-Minute walking test {#S0002-S2004-S3004}

The 6MWT was performed using a method that complied with the ATS Guidelines.[@CIT0019] Percutaneous oxygen saturation (SpO~2~) and pulse rate were recorded using a wrist-worn pulse oximeter capable of automatic remote monitoring (WristOX~2~™, Model 3150; Philips Electronics Japan Co., Ltd., Tokyo, Japan). All patients were instructed to walk as far as possible over a 6-min period. The walking distance (m), SpO~2~, heart rate, and modified Borg scale (BS) rating before and immediately after the walking test were analyzed.

Statistical analysis {#S0002-S2005}
--------------------

To compare the decreases in IC from IC~rest~ before and after treatment as indexes of DLH, we set conditions for statistical analyses with an examination power of 80%, an effect size of 0.4, and significance probability of 5%. The effect size was calculated in a previous study of the effects of bronchodilators on DLH by MPIH.[@CIT0013] The required sample size was calculated to be 38. The classification of COPD severity was based on airflow obstruction classification according to the GOLD criteria.[@CIT0005] The values in the text, tables, and figures are expressed as means ± SEM. Wilcoxon's signed rank test was used for comparison of each outcome before and after treatment. Spearman's rank correlation coefficient was used for a single regression analysis between IC change due to treatment and FEV~1~, 6MWD, or BS change. In all analyses, *P* \<0.05 was taken to indicate statistical significance. SPSS ver. 22 software was used for statistical analyses (SPS Inc., Chicago, IL).

Results {#S0003}
=======

Five of the 38 registered patients dropped out of the study for hospitalization due to gastrointestinal disorder, discontinuation of hospital visits for unknown reasons, refusal to undergo examination after treatment, hospitalization due to exacerbation of respiratory diseases, and not meeting the criteria of COPD after registration into the study in one patient each. The results were not trough values, as the after treatment examination was conducted following inhalation as usual.

Characteristics of patients and comparison of lung functions before and after treatment {#S0003-S2001}
---------------------------------------------------------------------------------------

[Table 1](#T0001){ref-type="table"} shows the basic physical findings, smoking history, medication history, and the results before and after treatment for each lung function along with the questionnaire responses. The study population included patients with mild to severe COPD as determined by the classification of airflow limitation severity using %FEV~1~,[@CIT0005] with 60% of all subjects showing moderate disease status. FEV~1~, %FEV~1~, and FEV~1~/FVC (forced vital capacity) ratio were significantly higher after treatment compared with before treatment (mean differences: FEV~1~, 161±4 mL; %FEV~1~, 5.4±1.4%; FEV~1~/FVC, 1.7±0.5%), while CAT was lower after treatment (mean differences: CAT, −2.1±0.8, MRC, −0.2±0.2).Table 1Characteristics of patients and comparison of lung function before and after treatmentBeforeAftern3333Age, years76.2±1.2Sex (male/female)32/132/1Smoking history, pack × year53.3±5.8 Past smoker, n30 Current smoker, n3BMI, kg/m^2^22.7±0.4CAT13.7±1.410.8±1.2\*mMRC1.3±0.21.0±0.2%VC, %101.1±2.8105.1±2.2\*IC, L2.32±0.092.32±0.06FEV~1~, L1.58±0.101.67±0.08 \*\*FEV~1~, %61.1±3.263.9±2.6 \*\*FEV~1~/FVC, %51.4±1.951.6±1.8 \*\*%FRC, %99.7±3.9%RV, %158.8±8.3%TLC, %125.6±3.4RV/TLC, %42.4±1.8%DLCO, %67.4±3.5GOLD stage (1, 2, 3, 4)4/21/7/1Treatment with inhaled agents at before including study No drug, n5 LAMA, n13 LABA, n2 LAMA+LABA, n4 LABA+ICS, n2 LAMA±LABA±ICS, n7[^1][^2]

Comparison of DLH following MPIH and 6MWT before and after treatment {#S0003-S2002}
--------------------------------------------------------------------

[Table 2](#T0002){ref-type="table"} shows the results of comparing DLH by MPIH and exercise tolerance before and after treatment. −IC~20~, −IC~30~, and −IC~40~ were significantly decreased after treatment (mean differences: −IC~20~, −0.12±0.06 L; −IC~30~, −0.11±0.05 L; −IC~40~, −0.13±0.06 L) ([Figure 3](#F0003){ref-type="fig"}). IC~20~, IC~30~, and IC~40~ were significantly increased after treatment (mean differences: IC~rest~, 0.04±0.06 L; IC~20~, 0.15±0.06 L; IC~30~, 0.15±0.04 L; IC~40~, 0.17±0.05 L). In addition, ΔIC was significantly decreased after treatment. The 6MWD was significantly increased after treatment compared with the value before treatment (mean difference: 14.6±8.4 m).Table 2Comparison of dynamic lung hyperinflation following hyperventilation and 6-min walking test (6MWT) before and after treatmentBeforeAftern3333IC~rest~, L2.39±0.082.42±0.09IC~20~, L2.25±0.092.41±0.09 \*IC~30~, L2.12±0.092.27±0.09 \*\*IC~40~, L1.99±0.102.15±0.10 \*\*--IC~20~, L--0.13±0.05−0.02±0.05 \*--IC~30~, L--0.27±0.05 ^††^−0.16±0.06 \*^†^--IC~40~, L--0.40±0.06 ^††^−0.27±0.06 \*^††^ΔIC~20~, %--5.6±2.20.5±2.5 \*ΔIC~30~, %--11.6±2.3 ^††^−5.5±2.8 \*^†^ΔIC~40~, %--16.9±2.7 ^††^−10.8±2.7 \*\*^††^6MWD, m460.2±19.4477.1±18.4 \*Pre SpO~2~, %95.3±0.395.2±0.4Lowest SpO~2~, %87.3±0.987.9±0.9PR~min~, bpm73.4±2.372.4±2.6PR~max~, bpm115.0±2.4113.5±3.1BS~min~,0.4±0.20.3±0.2BS~max~,5.2±0.54.6±0.4[^3][^4] Figure 3Comparison of dynamic lung hyperinflation following hyperventilation before and after treatment. \**P*\<0.05 vs before combined treatment with tiotropium and olodaterol.**Abbreviations:** Tio, Tiotropium; Olo, Olodaterol; IC, inspiratory capacity; bpm, breaths/min; IC~rest~, IC at rest; −IC~20~, decrease in IC from IC~rest~ to IC at 20 bpm; −IC~30~, decrease in IC from IC~rest~ to IC at 30 bpm; −IC~40~, decrease in IC from IC~rest~ to IC at 40 bpm.

Correlation of changes in DLH, FEV~1~, exercise tolerance, and dyspnea with treatment {#S0003-S2003}
-------------------------------------------------------------------------------------

[Table 3](#T0003){ref-type="table"} shows the correlations between change in DLH after treatment and the changes in FEV~1~, 6MWD, and maximum BS. There were no significant correlations between changes in IC, FEV~1~, 6MWD, or BS~max~ with treatment. The scatter plot in [Figure 4](#F0004){ref-type="fig"} shows the correlations of changes in values with treatment between 6MWD and FEV~1~, IC~40~, or −IC~40~ and between −IC~40~ and FEV~1~.Table 3Correlation of changes in DLH, FEV~1~, exercise tolerance, and dyspnea with treatmentFEV~^1^~ (L)6MWD (m)BS~max~IC~rest~0.300.250.28IC~20~0.060.050.06IC~30~0.220.150.18IC~40~0.130.180.06--IC~20~−0.23−0.20--0.17--IC~30~−0.06−0.14--0.13--IC~40~−0.17−0.12--0.14ΔIC~20~−0.24−0.18--0.09ΔIC~30~−0.01−0.05--0.10ΔIC~40~−0.03−0.02−0.17[^5] Figure 4Correlations of changes in value associated with treatment between 6MWD and FEV~1~(**A**), IC~40~ (**B**) or −IC~40~ (**C**) and between IC~40~ and FEV~1~(**D**). IC~40~, inspiratory capacity (IC) following 30-s hyperventilation at 40 breaths/min; −IC~40~, change in IC at rest to IC~40.~The value of change associated with treatment was calculated as the post-value minus the pre-value.**Abbreviations:** Ch, change in value by treatment; FEV~1~, forced expiratory volume in 1 s; 6MWD, 6-min walking distance; IC, inspiratory capacity; IC~40~, IC at 40 breaths/min; −IC~40~, decrease in IC from IC at rest to IC~40.~

Discussion {#S0004}
==========

The present study was performed to elucidate the effects of combined treatment with tiotropium and olodaterol on DLH following MPIH. Thirty-three patients completed the study and five dropped out. Most of the 33 patients had mild to moderate COPD. −IC and ΔIC decreased significantly and IC after each hyperventilation increased after treatment. In addition, lung functions, subjective symptoms, and exercise tolerance improved significantly with treatment for 8 weeks. There were no correlations between the changes in DLH and exercise tolerance, FEV~1~, or dyspnea. The results of this study revealed the effects of combined treatment with tiotropium and olodaterol on DLH following MPIH.

Dynamic lung hyperinflation {#S0004-S2001}
---------------------------

Previous studies demonstrated improvements in DLH using combinations of LAMA and LABA for DLH evaluated by MPIH methods and exercise loading. In a previous study using MPIH, the treatment groups receiving tiotropium/indacaterol (5/150 μg), showed significant increases in IC~20~, IC~30~, and IC~40~ from resting IC of 0.10, 0.15, and 0.19 L in, respectively.[@CIT0013] The results of the present study were similar to those reported previously as olodaterol and indacaterol have similar efficacy in patients with COPD.[@CIT0020] However, we newly elucidated the effects of combined treatment with tiotropium and olodaterol on DLH following MPIH. As IC measurements were substituted for EELV,[@CIT0010] the changes in IC were due to the improvement of EELV. The DLH associated with increased EELV was improved by the increase in the exhalation flow rate by LAMA.[@CIT0021] Fujimoto et al, reported that EELV and IC were improved by bronchodilators based on measurements by MPIH.[@CIT0022] Therefore, improvement of DLH was suspected to have been due to increased expiratory flow by tiotropium and olodaterol in the present study.

In a study using exercise loading, O'Donnell et al, compared a combination of tiotropium and olodaterol (2.5/5 and 5/5 μg) with placebo or each agent administered alone as monotherapy.[@CIT0009] They measured periodical IC during exercise loading and IC decrease during exercise to evaluate DLH, and reported that resting IC increased significantly by 0.245 L after treatment compared to placebo. Furthermore, IC during exercise increased by about 0.1--0.15 L after treatment compared to each monotherapy. In the present study, however, the resting IC was increased by 0.04±0.06 L, and IC by MPIH showed a mean increase of 0.17±0.05 L after treatment. In contrast to the previous study, only the resting IC did not show a significant improvement in the present study. Resting IC did not improve in a study of the effects of combined LAMA and LABA treatment in the study of Fujimoto et al[@CIT0013], but improvement was observed in another study by Ichinose et al[@CIT0023]. Further studies of the effects on resting IC are required because the results were not consistent with previous studies of bronchodilators in Japanese subjects with the same characteristics.

Lung function {#S0004-S2002}
-------------

Previous studies have mainly reported the effects of combined treatment with tiotropium and olodaterol on lung function and subjective symptoms. Beeh et al, compared the effects between five groups, ie, tiotropium/olodaterol combination (2.5/5 and 5/5 μg), each monotherapy, and placebo.[@CIT0007] They reported that the group receiving combined tiotropium/olodaterol treatment showed significantly improved FEV~1~ compared to the other groups. In the present study, the combination treatment with tiotropium and olodaterol showed improvements in subjective symptoms and FEV~1~, consistent with previous studies. However, these improvements were milder in the present study compared with previous reports. For example, Beeh et al, reported that Peak~0-3~ FEV~1~ was increased by 0.411 L compared to baseline by 6 weeks of combined treatment with tiotropium/olodaterol (5/5 μg),[@CIT0007] while an improvement of 0.161±0.004 L compared to baseline was observed after 8 weeks in the present study. Dave et al, reported a transition dyspnea index of 1.67--1.85 as a subjective symptom compared to baseline, representing an improvement of \>1 in meaningful Minimal Clinical Important Difference (MCID) for dyspnea by treatment with tiotropium/olodaterol (5/5 μg),[@CIT0024] while CAT showed improvement of 2.1±0.8 compared to baseline, representing an improvement of \<3 in MCID of CAT in the present study. Therefore, improvements in subjective symptoms and lung function were milder in the present study compared to previous reports. This was probably because the subjects in the present study were older than those in these previous studies. Tashkin et al, reported that advanced age was one of the baseline characteristics associated with poor response to bronchodilators in the UPLIFT study, which investigated the long-term effects of tiotropium for mild to moderate disease.[@CIT0025] While the average age of subjects in the previous clinical studies of tiotropium and olodaterol was 60 years, the subjects in the present study had an average age of 70 years.[@CIT0006],[@CIT0009] In addition, the mean age of subjects in a study of the same treatment regimen in Japanese subjects by Ichinose et al, was 72 years.[@CIT0023] Ichinose et al, reported that FEV~1~ showed mild improvement from a baseline of 1.228 --1.275 L after the same treatment as applied in the present study. Therefore, it was considered that the mild improvements of subjective symptoms and lung function in the present study were because of the advanced age of the subjects.

Exercise tolerance {#S0004-S2003}
------------------

Improvement of exercise tolerance was also observed in the present study, because 6MWD showed a significant increase after treatment. However, 6MWD showed an improvement of \<25--30 m in MCID of 6MWD in the present study.[@CIT0026] This was considered to have been due to the milder severity of disease in our patients. O'Donnell et al, reported that LAMA and LABA maintenance therapy in patients with COPD provide sustained lung volume reduction as a result of improved tidal expiratory flow rates and lung emptying, with reduced resting and exercise lung hyperinflation, and a delay in the mechanical limitation to ventilation, with consequent alleviation of exertional dyspnea and exercise capacity.[@CIT0021] In addition, combined tiotropium and olodaterol treatment were reported to affect exercise capacity.[@CIT0009] Therefore, the reduction in DLH was considered to have improved exercise tolerance in the present study. However, Ichinose et al, reported improvement in a subgroup with only severe COPD in a study with administration of the same treatment regimen in Japanese subjects.[@CIT0023] Although Ichinose demonstrated improvements only in severe COPD, the patients in the present study had mild to moderate COPD. Several studies indicated that exercise capacity is improved in the subgroup with more severe COPD,[@CIT0023],[@CIT0027] while the results of the present study in patients with mild to moderate COPD were consistent with similar studies of tiotropium/olodaterol in patients with less severe disease. Ferguson et al, reported greater improvements compared to baseline after 24 weeks of tiotropium/olodaterol combination treatment in the subgroup with less severe COPD.[@CIT0028] Therefore, further studies are required to examine the improvement of exercise capacity in relation to severity, and the results reported to date have been inconsistent.

Correlations of changes in DLH, FEV~1~, exercise tolerance, and dyspnea with treatment {#S0004-S2004}
--------------------------------------------------------------------------------------

There were no correlations between changes associated with treatment in DLH and 6MWD or maximum BS. The results of the present study were different from those reported by O'Donnell et al[@CIT0021], which was probably due to differences in the methods used for evaluation of DLH between the two studies. O'Donnell et al, reported correlations between changes in DLH, exercise tolerance, and dyspnea during exercise after tiotropium monotherapy in a randomized controlled trial. In this previous study, DLH was evaluated based on the decrease in IC during exercise loading or just after exercise. On the other hand, hyperventilation and spirometer were used to evaluate DLH in the present study. It is unclear whether DLH induced by exercise loading is equivalent to DLH induced by MPIH. We are currently engaged in experiments to determine whether DLH determined by exercise loading and DLH determined by MPIH are comparable, and plan to report our findings in the near future.

Limitations {#S0004-S2005}
-----------

The present study had several limitations. First, this was a pre- and post-treatment comparative study, and there was no control group. Comparison with placebo or conventional treatment was not performed. Therefore, it is possible that various confounding factors may have affected the results. Second, most of the patients had moderate disease status, and the effects on DLH may have been underestimated. As previous clinical trials examined combination therapy mainly in patients with mild to severe disease,[@CIT0006],[@CIT0009] the results of the present study may have been different if the disease status in the majority of our patients had been moderate to severe. Third, the study may have been underpowered because five patients dropped out. However, there was a significant difference in the main outcome in the 33 patients included in the analysis, and post hoc analysis demonstrated that the statistical power was ≥80%. Fourth, the washout period used in the present study was short. The recommended washout period is five times the half-life.[@CIT0029] As the half-lives of tiotropium, olodaterol, and ICS are 25, 7.5, and 14.4 hrs, respectively, the washout period for tiotropium was too short in the present study.

Conclusion {#S0005}
==========

In conclusion, the results of this study indicated that the combination of tiotropium and olodaterol is effective for improvement of DLH following hyperventilation. In addition, this study showed a difference in the response of DLH due to exercise loading to treatment compared to previous studies. Therefore, further studies are required to examine the differences in responses between exercise loading and hyperventilation.
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[^1]: **Notes:** Values represent mean ± standard error of the mean; \**p*\<0.05 and \*\**p*\<0.01 vs before treatment.

[^2]: **Abbreviations:** BMI, body mass index; CAT, COPD assessment test; mMRC, Modified Medical Research Council dyspnea scale, VC, vital capacity; IC, inspiratory capacity; FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity; FRC, functional residual capacity; RV, residual volume; TLC, total lung capacity; DLCO, lung-diffusion capacity for carbon monoxide; LAMA, long-acting muscarinic antagonist; LABA, long-acting beta 2 agonist; ICS, inhaled corticosteroid.

[^3]: **Notes:** Values represent mean ± standard error of the mean; \**p*\<0.05 and \*\**p*\<0.01 vs before treatment; ^†^*p*\<0.05 and ^††^*p*\<0.01 vs --IC~20~ or ΔIC~20~.

[^4]: **Abbreviations:** IC, inspiratory capacity; bpm, breaths/min; IC~rest~, IC at rest; IC~20~, IC at 20 bpm; --IC~20~, decrease in IC from IC~rest~ to IC~20~; ΔIC~20~, change in IC from IC~rest~ to IC~20~; IC~30~, IC at 30 bpm; --IC~30~, decrease in IC from IC~rest~ to IC~30~; ΔIC~30~, change in IC from IC~rest~ to IC~30~; IC~40~, IC at 40 bpm; --IC~40~, decrease in IC from IC~rest~ to IC~40~; ΔIC~40~, change in IC from IC~rest~ to IC~40~; 6MWD, 6-min walking distance; SpO~2~, percutaneous oxygen saturation; PR~min~, minimum pulse rate; PR~max~, maximum pulse rate; BS~min~, minimum modified Borg scale; BS~max~, maximum modified Borg scale.

[^5]: **Notes:** Values represent the means. The value of change associated with treatment was calculated as the post-value minus the pre-value.

    **Abbreviations:** IC, inspiratory capacity; IC~rest~, IC at rest; IC~20~, IC at 20 bpm; --IC~20~, decrease in IC from IC~rest~ to IC~20~; ΔIC~20~, change in IC from IC~rest~ to IC~20~; IC~30~, IC at 30 bpm; --IC~30~, decrease in IC from IC~rest~ to IC~30~; ΔIC~30~, change in IC from IC~rest~ to IC~30~; IC~40~, IC at 40 bpm; --IC~40~, decrease in IC from IC~rest~ to IC~40~; ΔIC~40~, change in IC from IC~rest~ to IC~40~. FEV~1~, forced expiratory volume in 1 s; 6MWD, 6-min walking distance; BS~max~, maximum modified Borg scale.
